Pharmacoepigenetics (2nd Ed.)
Translational Epigenetics Series

Coordinator: Cacabelos Ramón

Language: English

242.37 €

Not Yet Published

Add to cartAdd to cart
Publication date:
1150 p. · 21.4x27.6 cm · Hardback
Pharmacoepigenetics, Second Edition, Volume Ten in the Translational Epigenetics series, is a comprehensive reference on the role of epigenetics and epigenomics in drug discovery and development. Here, leading international researchers from across academia, clinical settings, and the pharmaceutical industry discuss the influence of epigenetics and epigenomics in human pathology, epigenetic biomarkers for disease prediction, diagnosis, and treatment, current epigenetic drugs, and the application of epigenetic procedures in drug development. Throughout the book, chapter authors offer a balanced and objective discussion of the future of pharmacoepigenetics and its crucial contribution to the growth of precision and personalized medicine.

This new edition has been fully revised to address recent advances in epigenetics, from new natural and synthetic compounds with epigenetic effects to the role of epigenetics in the pathogenesis of a growing number of complex diseases, including further cancers, cardiovascular disorders, and brain disorders. Newly identified molecular components in the functional architecture of the epigenetic machinery, as well as practical and relevant pharmacoepigenetics topics related to COVID-19 and other world health challenges are also discussed.

I. General Principles 1.The Epigenetic Machinery in the Life Cycle 2. Pharmacoepigenetics: Basic Principles for Personalized Medicine 3. Pharmacoepigenetic Processors 4. Epigenetic regulation of genes involved in drug metabolism 5. MicroRNA-Dependent Gene Regulation of the Human Cytochromes P450 6. Epigenetic regulation of transporter genes 7. Pathoepigenetics: The Role of Epigenetic Biomarkers in Disease Pathogenesis II. Drug Development and Drug-related events 8. Epigenetic Drugs 9. Pharmacoepigenetics of Novel Nucleoside DNA Methyltransferase Inhibitors 10. Pharmacoepigenetics: Novel Mechanistic Insights in Drug Discovery and Development Targeting Chromatin-Modifying Enzymes 11. Pharmacoepigenetics of EZH2 Inhibitors 12. Regulators of Histone Acetylation: Bromodomain Inhibitors 13. Bromodomain Inhibition and Its Application to Human Disease 14. Pharmacoepigenetics of Brassica-Derived Compounds 15. Pharmacological Nicotinamide: Mechanisms Centered Around SIRT1 Activity 16. Epigenetic-related Drug Resistance 17. Toxicoepigenetics III. Pharmacoepigenetics of Cancer 18. Epigenetics of Aging and Cancer: A Comprehensive Look 19. Epigenetic Drug Discovery for Cancer 20. Pharmacoepigenetics of Histone Deacetylase Inhibitors in Cancer 21. Pharmacoepigenetics of LSD1 Inhibitors in Cancer 22. Epigenetic effects of AntiGan in Cancer 23. Pharmacoepigenetic Considerations for the Treatment of Breast Cancer 24. Pharmacoepigenetics of Acute Myeloid Leukemia 25. Therapeutic Potential of Pharmacoepigenetics in Cholangiocarcinoma 26. Pharmacoepigenetics of Gastrointestinal disorders and Cancer 27. Pharmacoepigenetics of Chinese Herbal Components in Cancer IV. Pharmacoepigenetics of Cardiovascular disease and Related disorders 28. Epigenetics and Pharmacoepigenetics of myocardial infarction 29. Epigenetics and Pharmacoepigenetics of Arteriosclerosis 30. Epigenetics and Pharmacoepigenetics of Hypertension 31. Pharmacoepigenetics of Ancoagulants 32. Epigenetics in Doxorubicin Cardiotoxicity 33. Epigenetic effects of CardioSar in cardiovascular disorders V. Pharmacoepigenetics of Central Nervous System disorders 34. Epigenetics and Pharmacoepigenetics of Neurodevelopmental and Neuropsychiatric Disorders 35. Pharmacoepigenetics and Toxicoepigenetics in Neurodevelopmental Disorders 36. Pharmacoepigenetics of Autism Spectrum Disorder 37. Pharmacoepigenetics of Antipsychotic Drugs 38. Pharmacoepigenetics of Bipolar Disorder 39. Pharmacoepigenetics of Major Depression 40. Epigenetics and Pharmacoepigenetics of Vestibulocochlear disorders 41. Epigenetics and Pharmacoepigenetics of Visual disorders 42. Epigenetics and Pharmacoepigenetics of Age-Related Neurodegenerative Disorders 43. Epigenetic effects of Nosustrophine in Alzheimer’s disease 44. Epigenetic effects of Atremorine in Parkinson’s disease 45. Pharmacoepigenetics and Pharmacoepigenomics of Valproate in Neurodegenerative Disease 46. Pharmacoepigenetics of Memantine in Dementia VI. Pharmacoepigenetics of Metabolic and Endocrine disorders 47. Pharmacoepigenetics in Type 2 Diabetes Mellitus 48. Epigenetics and Pharmacoepigenetics of hypercholesterolemia and lipid metabolism disorders 49. Pharmacoepigenetics of Statins 50. Epigenetics and Pharmacoepigenetics of Thyroid disorders VII. Pharmacoepigenetics of Immunological and Inflammatory disorders 51. Pharmacoepigenetics of Immunological Disorders 52. Pharmacoepigenetics of Rheumatic Disorders 53. Epigenetics and Pharmacoepigenetics of Skin disorders 54. Pharmacoepigenetics of Systemic Lupus Erythematosus VIII. Nutritional Epigenetics 55. Nutriepigenetics 56. Epinutraceuticals: Novel biomolecules with epigenetic effects IX. Epigenetics and Pharmacoepigenetics of infectious disorders 57. Pharmacoepigenetic of bacterial infections 58. Pharmacoepigenetics of viral infections 59. Pharmacoepigenetics of COVID-19 X. Mendelian epigenetic disorders 60. Pharmacoepigenetics of Mendelian disorders associated with the epigenetic machinery

Dr. Ramón Cacabelos is Professor and Chairman of Genomic Medicine and President of the EuroEspes Biomedical Research Center, Corunna, Spain. He received his M.D. from Oviedo University, Oviedo, Spain; Ph.D. from Santiago University, Santiago de Compostela, Spain; and D.M.Sci. (Psychiatry) from Osaka University Medical School, Osaka, Japan. After a decade at the Department of Psychiatry in Osaka, he returned to Spain and focused his research activity on the genomics, epigenomics and pharmacogenomics of brain disorders, with special emphasis on neurodegenerative disorders (Alzheimer’s disease, Parkinson’s disease). He has published over 700 papers and 30 books and is Editor-in-Chief of the first World Guide for Drug Use and Pharmacogenomics and President of the World Association of Genomic Medicine.
  • Fully examines the influence of epigenetics and epigenomics in human pathology, epigenetic biomarkers for disease prediction, diagnosis, treatment, current epigenetic drugs, and the application of epigenetic procedures in drug development
  • Features chapter contributions from leading international researchers in academia, clinical settings, and the pharmaceutical industry
  • Instructs researchers, students, and clinicians in better interpreting and employing pharmacoepigenetics in drug development, efficiency, and safety
  • Incorporates recent advances, including epigenetic drugs and biomolecules with epigenetic effects in cancer, cardiovascular disorders, brain disorders, and COVID-19
  • Includes chapter definitions, key words, and summaries to reinforce understanding, as well clinical research case studies illustrating key research in the field